昂丹司琼制剂安全性风险分析

doi:10.19803/j.1672-8629.20240458

摘要/Abstract

摘要： 目的分析昂丹司琼制剂的安全性风险,为临床合理用药提供参考。方法对我国药品不良反应监测数据库（2004 年1 月1日至2022年9月30日）、世界卫生组织（WHO）药品不良反应监测数据库（建库至2022年10月31日）以及其他国内外数据库（建库至2023年12 月31日）的不良反应报告以及国内外风险控制措施等相关资料进行整理与分析。结果昂丹司琼严重不良反应报告中,过敏性休克、呼吸困难、肝功能损害不良反应突出;在孕期使用昂丹司琼有导致胎儿唇腭裂的风险,产妇若在分娩前后使用本品,应暂停哺乳。结论医疗机构需关注昂丹司琼制剂的致畸风险,在孕妇中使用应权衡利弊。同时,药品上市许可持有人应及时完善产品说明书,加强和医疗机构的风险沟通,促进药品的合理使用。

关键词: 昂丹司琼, 药品不良反应, 胎儿, 致畸风险, 唇腭裂, 监管措施, 说明书

Abstract: Objective To analyze the risks to safety posed by Ondansetron in China in order to provide reference for clinical rational drug use. Methods The individual cases of adverse drug reactions retrieved from China adverse drug reaction database (from January 1, 2004 to September 30, 2022) and WHO Vigilyze (from inception to October 31, 2022) and other databases (from inception to December 31, 2023) were analyzed. Results In the serious adverse reaction report of ondansetron, adverse reactions such as anaphylactic shock, dyspnea, and liver dysfunction are prominent. ondansetron in pregnancy is associated with a risk of cleft lip and palate. If pregnant women use ondansetron before and after delivery, breastfeeding should be suspended. Conclusion Medical institutions should pay attention to the teratogenic risk of Ondansetron and weigh the risk and benifit before using it in pregnant women. The drug marketing authorization holder should update the drug labeling in time, strengthen the risk communication with medical institutions, and promote the rational use of medicines.

Key words: ondansetron, drug adverse reaction, fetus, teratogenic risk, cleft lip and palate, regulatory measures, instruction

中图分类号:

R994.11

孟康康, 夏玉坤. 昂丹司琼制剂安全性风险分析[J]. 中国药物警戒, 2024, 21(9): 1034-1038.

MENG kangkang, XIA Yukun. Risks to safety of Ondansetron preparations[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1034-1038.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240458

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I9/1034

参考文献

[1] Medicines & Healthcare products Regulatory Agency. Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy[EB/OL]. (2020-01-27)[2024-03-30]. https://www.gov.uk/drug-safety-update/ondansetron-small-increased-risk-of-oral-clefts-following-use-in-the-first-12-weeks-of-pregnancy.
[2] National Healthcare Security Administration. List of national basic medical insurance, industrial injury insurance and maternity insurance drugs (2022 version) [EB/OL].(2023-01-18)[2024-03-10]. http://www.nhsa.gov.cn/art/2023/1/18/art_104_10078.html.
[3] ZHAO W.Effect of ondansetron on prevention and treatment of postoperative nausea and vomiting in patients with preoperative anxiety[D]. Kunming: Kunming University of Science and Technology, 2023.
[4] WANG XX, XIN ZQ, ZHANG CX, et al.Systematic review of effects of ondansetron hydrochloride injection in preventing non-nausea and vomiting adverse drug reactions after cesarean section[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2021, 21(2): 213-218.
[5] YU XM, ZHOU K.Effect of different doses of ondansetron on preventing nausea and vomiting after gynecological laparoscopic surgery[J]. Clinical Research and practice(临床医学研究与实践), 2021, 6(24): 82-84.
[6] CHEN WZ, LI DK, CHEN YJ.Comparison of the efficacy of tolansetron and ondansetron in the treatment of postoperative nausea and vomiting after general anesthesia in patients with thoracic tumors[J]. Journal of North Pharmacy(北方药学), 2022, 19(8): 123-125.
[7] LIU YH, CHEN L.Data mining for adverse events of 5-HT3 receptor antagonists based on FAERS database[J]. Anti-Tumor Pharmacy(肿瘤药学), 2022, 12(1): 92-99.
[8] HUYBRECHTS KF, HERNÁNDEZ-DÍAZ S, STRAUB L, et al. Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring[J]. JAMA, 2018, 320(23): 2429-2437.
[9] ZAMBELLI-WEINER A, VIA C, YUEN M, et al.First trimester ondansetron exposure and risk of structural birth defects[J]. Reproductive Toxicology, 2019, 83: 14-20.
[10] PARKER SE, VAN BENNEKOM C, ANDERKA M, et al.National birth defects prevention study. ondansetron for treatment of nausea and vomiting of pregnancy and the risk of specific birth defects[J].Obstet Gynecol , 2018 , 132(2): 385-394.
[11] EMEA. PRAC recommendations on signals adopted at the 8-11 July2019 PRAC meeting[EB/OL]. (2019-08-06)[2024-03-30]. https://www.ema.europa.eu/en/documents/pracrecommendation/prac-recommendations-signals-adopted-8-11-july-2019-prac-meeting_en.pdf.
[12] NMPA. Announcement of the National Medical Products Administration on the amendment of the manual for Ondansetron (No.12 of2023)[EB/OL]. (2023-01-16)[2024-03-10]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20230116173005189.html.
[13] LI X, ZHANG SQ.Interpretation of the“2018 Guidelines for the Diagnosis and Treatment of nausea and vomiting in Pregnancy” of the American College of Obstetricians and Gynecologists[J]. Chinese Journal of Practical Gynecology and Obstetrics(中国实用妇科与产科杂志), 2018, 34(4): 409-412.
[14] OUYANG ZB, YIN Q, QUAN S, et al.Interpretation of Chinese, American Canadian and British guidelines for the diagnosis and treatment of nausea and vomiting during pregnancy and hyperemesis gravidarum[J]. Progress in Obstetrics and Gynecology(现代妇产科进展), 2017, 26(11): 875-877.
[15] Department of Obstetrics and Gynecology, Chinese Medical Association. Expert Consensus on Diagnosis and Clinical Management of Hyperemesis gravidarum (2015)[J]. Chinese Journal of Obstetrics and Gynecology(中华妇产科杂志), 2015, 50(11): 801-804.